Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients

Clinical Therapeutics

Volumn 29, Issue 11, 2007, Pages 2395-2405

  Kanaan, Abir O ^a,b,c   Silva, Matthew A ^a,b,c   Donovan, Jennifer L ^a,c,d   Roy, Tara ^c,d   Al Homsi, A Samer ^c,d  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b Saint Vincent Hospital   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d University of Massachusetts Memorial Medical Center Worcester   (United States)

Author keywords

fondaparinux.; low molecular weight heparin; prophylaxis; unfractionated hepatin; venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ARTICLE; BLEEDING; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONFIDENCE INTERVAL; DATA ANALYSIS; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG EFFICACY; EMBASE; FOLLOW UP; GENERAL ASPECTS OF DISEASE; HUMAN; LUNG EMBOLISM; MEDLINE; META ANALYSIS; PATIENT SELECTION; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; DATA INTERPRETATION, STATISTICAL; DRUG UTILIZATION; FEMALE; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HOSPITALIZATION; HUMANS; MALE; ODDS RATIO; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOSIS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

EID: 37449006735     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.11.015     Document Type: Article

References (37)

1. Goldhaber S. Epidemiology of pulmonary embolism. Semin Vasc Med 1 (2001) 139-146
2. Stratton M., Anderson F., Bussey H., et al. Prevention of venous thromboembolism: Adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 160 (2000) 334-340
3. Kahn S. Frequency and determinants of the postthrom- botic syndrome after venous thromboembolism. Curt Opin Pulm Med 12 (2006) 299-303
4. Cade J. High risk of the critically ill for venous thromboembolism. Crit Care Med 10 (1982) 448-450
5. Belch J., Lowe G., Ward A., et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 26 (1981) 115-117
6. Hirsch D., Ingenito E., and Goldhaber S. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 274 (1995) 335-337
7. Sitverstein M., Heir J., Mohr D., et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 158 (1998) 585-593
8. McGarry L., and Thompson D. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely ill medical inpatients in community practice. Clin Ther 26 (2004) 419-430
9. O'Brien J., and Caro J. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications. Pharmacoeconomics 20 (2002) 603-615
10. Anderson Jr. F., Wheeler H., Goldberg R., et al. A population- based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 151 (1991) 933-938
11. Prandoni P., Lensing A., Cogo A., et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125 (1996) 1-7
12. Geerts W., Pineo G., Heit J., et al. Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 SuppI 3 (2004) 3385-4005
13. Goldhaber S., Tapson V., and for the DVT FREE Steering Committee. A prospective registry of 5451 patients with ultrasound-confirmed deep vein thrombosis. AmJ Cardiol 93 (2004) 259-262
14. Shojania K., Duncan B., McDonald K., et al. Making health care safer: A critical analysis of patient safety practices. Evid Rep Technol Assess (Suture) 43 (2001) i-x
15. Shojania K., Duncan B., McDonald K., et al. Making health care safer: A critical analysis of patient safety practices. Evid Rep Technol Assess (Suture) 43 (2001) 1-668
16. Heit J., Sitverstein M., Mohr D., et al. Risk factors for deep vein thrombosis and pulmonary embolism: A population-based case-control study. Arch Intern Med 160 (2000) 809-815
17. Gardlund B., and for the Heparin Prophylaxis Study Group. Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases. Lancet 347 (1996) 1357-1361
18. Halkin H., Goldberg J., Modan M., and Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 96 (1982) 561-565
19. Cohen A., Davidson B., Gallus A., et al. Efficacy and safety of fonda-parinux for the prevention of venous thromboembolism in older acute medical patients: Randomised placebo controlled trial. BMJ 332 (2006) 325-329
20. Hohenstein E., Tsakiris D., and Bircher A. Delayed-type hypersensitivity to the ultra-low-molecular-weight heparin fondaparinux. Contact Dermatitis 51 (2004) 149-151
21. Arixtra (fondaparinux sodium) injection [prescribing information] (2005), GlaxoSmithKline, Research Triangle Park, NC
22. Maetzke J., Hinrichs R., Schneider L., and Scharffetter-Kochanek K. Unexpected delayed-type hypersensitivity skin reactions to the ultra-low-molecular-weight heparin fondaparinux. Allergy 60 (2005) 413-415
23. Jadad A., Moore I., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Control Clin Trials 17 (1996) 1-12
24. Moher D., Jadad A., and Tugwell P. Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 12 (1996) 195-208
25. DerSimonian R., and Laird N. Metaanalysis in clinical trials. Control Clin Trials 7 (1986) 177-188
26. Higgins J., Thompson S., Deeks J., and Airman D. Measuring inconsistency in meta-analyses. BMJ 327 (2003) 557-560
27. Samama M., Cohen A., Darmon J., et al., for the Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N EnglJ Med 341 (1999) 793-800
28. Fraisse F., Holzapfel L., Couland J., et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 161 (2000) 1109-1114
29. Leizorovicz A., Cohen A., Turpie A., et al., for the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110 (2004) 874-879
30. Mahe I., Bergmann J., d'Azemar P., et al. Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical inpatients: A prospective randomised double-blind study. Eur J Clin Pharmacol 61 (2005) 347-351
31. Bergmann J., Neuhart E., and for the Enoxaparin in Medicine Study Group. A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. Thromb Haemost 76 (1996) 529-534
32. Lechler E., Schramm W., Flosbach C., and for the Prime Study Group. The venous thrombotic risk in non-surgical patients: Epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). Haemostasis 26 Suppl 2 (1996) 49-56
33. Harenberg J., Roebruck P., Heene D., and for the Heparin Study in Internal Medicine Group. Subcutaneous low-molecular-weight heparin versus standard heparin and the prevention of thromboembolism medical inpatients. Haemostasis 26 (1996) 127-139
34. Kleber F., Witt C., Vogel G., et al. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145 (2003) 614-621
35. Dahan R., Houlbert D., Caulin C., et al. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: A randomized double-blind trial. Haemostasis 16 (1986) 159-164
36. Harenberg J., Kallenbach B., Martin U., et al. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 59 (1990) 639-650
37. Kamphuisen P., and Agnelli G. What is the optimal pharmacological prophylaxis for the prevention of deep vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?. Thromb Res 119 (2007) 265-274